v3.26.1
Segment Information
 6 Months Ended
Jun. 30, 2026
Segment Reporting [Abstract]  
Segment Information
11. Segment Information
We have one reportable segment which focuses on the discovery and development of cancer therapeutics. The segment derives its revenue from the Purchase Agreement with Jazz (see Note 4, Collaboration Revenue).
Our chief operating decision maker (“CODM”) manages our operations on an integrated basis for the purpose of allocating resources. When evaluating our financial performance, our CODM regularly reviews total expenses and expenses by function and makes decisions using this information based on the performance of the enterprise as a whole. Our CODM primarily evaluates the performance of the enterprise based on results that have a direct impact on our available cash and cash equivalents and accordingly places less significance on non-cash expenses such as stock-based compensation and depreciation expenses in determining how to allocate resources.
Segment assets regularly reviewed by our CODM include measures of liquidity, primarily available cash and cash equivalents, and are consistent with the presentation of cash and cash equivalents reported in our condensed consolidated balance sheets.
The following is a summary of our segment and consolidated net income (loss), including significant segment expenses:
Three Months Ended
June 30,		Six Months Ended
June 30,
2026202520262025
(in thousands)
Collaboration revenue$21,000 $— $21,000 $— 
Less:
General and administrative support6,678 3,486 11,250 7,309 
Clinical development3,047 5,710 6,690 10,039 
Research and discovery1,028 3,537 3,183 6,856 
Manufacturing218 2,610 1,792 6,698 
Other segment expenses(a)
2,871 2,199 4,198 4,631 
Interest income277 850 710 1,847 
Interest expense(475)(1,301)(1,843)(2,564)
Loss on extinguishment of note payable(3,354)— (3,354)— 
Other income, net64 11 738 179 
Segment and consolidated net income (loss)$3,670 $(17,982)$(9,862)$(36,071)
(a) Other segment expenses includes non-cash expenses for stock-based compensation and depreciation expenses.